| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Defects, Congenital | 45 | 2023 | 1764 | 3.330 |
Why?
|
| Pulmonary Circulation | 18 | 2019 | 136 | 2.820 |
Why?
|
| Pulmonary Artery | 22 | 2020 | 525 | 2.480 |
Why?
|
| Blood Pressure | 24 | 2018 | 1521 | 1.550 |
Why?
|
| Models, Cardiovascular | 13 | 2018 | 209 | 1.540 |
Why?
|
| Cardiology | 5 | 2022 | 589 | 1.500 |
Why?
|
| Fontan Procedure | 11 | 2023 | 182 | 1.500 |
Why?
|
| Rheumatic Heart Disease | 5 | 2019 | 47 | 1.450 |
Why?
|
| Hypertension, Pulmonary | 16 | 2023 | 473 | 1.380 |
Why?
|
| Heart Ventricles | 12 | 2017 | 895 | 1.310 |
Why?
|
| Oxygen Consumption | 12 | 2023 | 398 | 1.220 |
Why?
|
| Hypoplastic Left Heart Syndrome | 9 | 2017 | 248 | 1.210 |
Why?
|
| Fetus | 7 | 2012 | 625 | 1.170 |
Why?
|
| Intensive Care Units, Pediatric | 9 | 2021 | 469 | 1.150 |
Why?
|
| Dobutamine | 7 | 2011 | 60 | 1.130 |
Why?
|
| Monitoring, Physiologic | 5 | 2021 | 517 | 1.100 |
Why?
|
| Cardiopulmonary Bypass | 11 | 2014 | 402 | 1.090 |
Why?
|
| Sheep | 22 | 2018 | 267 | 1.060 |
Why?
|
| Echocardiography, Doppler, Color | 2 | 2016 | 126 | 1.060 |
Why?
|
| Ventricular Function | 5 | 2018 | 101 | 1.030 |
Why?
|
| Blood Flow Velocity | 16 | 2019 | 505 | 0.970 |
Why?
|
| Aorta | 9 | 2020 | 696 | 0.950 |
Why?
|
| Ductus Arteriosus | 4 | 2019 | 50 | 0.940 |
Why?
|
| Transposition of Great Vessels | 7 | 2020 | 129 | 0.900 |
Why?
|
| Heart Atria | 5 | 2013 | 373 | 0.900 |
Why?
|
| Hemodynamics | 18 | 2023 | 1014 | 0.880 |
Why?
|
| Mass Screening | 6 | 2016 | 1571 | 0.850 |
Why?
|
| Coronary Circulation | 6 | 2018 | 271 | 0.800 |
Why?
|
| Aortic Coarctation | 2 | 2016 | 103 | 0.720 |
Why?
|
| Antihypertensive Agents | 5 | 2016 | 416 | 0.720 |
Why?
|
| Ventricular Function, Right | 5 | 2012 | 122 | 0.710 |
Why?
|
| Meconium Aspiration Syndrome | 4 | 2010 | 16 | 0.700 |
Why?
|
| Vascular Resistance | 9 | 2015 | 206 | 0.660 |
Why?
|
| Adrenergic beta-Agonists | 4 | 2014 | 138 | 0.660 |
Why?
|
| Leadership | 2 | 2022 | 271 | 0.660 |
Why?
|
| Regional Blood Flow | 9 | 2017 | 283 | 0.650 |
Why?
|
| Heart Arrest | 2 | 2021 | 373 | 0.650 |
Why?
|
| Ventricular Dysfunction, Right | 4 | 2004 | 85 | 0.650 |
Why?
|
| Vasoconstriction | 3 | 2010 | 108 | 0.650 |
Why?
|
| Endothelin-1 | 3 | 2014 | 64 | 0.620 |
Why?
|
| Patient Care Team | 3 | 2022 | 828 | 0.610 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type II | 2 | 2014 | 20 | 0.610 |
Why?
|
| Heart Septal Defects, Ventricular | 4 | 2011 | 138 | 0.600 |
Why?
|
| Critical Care | 4 | 2021 | 795 | 0.600 |
Why?
|
| Child | 53 | 2023 | 30347 | 0.600 |
Why?
|
| Arterial Switch Operation | 1 | 2017 | 21 | 0.590 |
Why?
|
| Cardiovascular Diseases | 5 | 2016 | 2289 | 0.580 |
Why?
|
| Ventricular Function, Left | 8 | 2014 | 615 | 0.580 |
Why?
|
| Cerebral Arteries | 1 | 2017 | 79 | 0.570 |
Why?
|
| Arterial Pressure | 1 | 2017 | 108 | 0.560 |
Why?
|
| Child, Preschool | 37 | 2023 | 16878 | 0.550 |
Why?
|
| Nitric Oxide | 9 | 2014 | 652 | 0.550 |
Why?
|
| Cardiologists | 1 | 2016 | 39 | 0.540 |
Why?
|
| Comprehension | 1 | 2017 | 123 | 0.540 |
Why?
|
| Ambulatory Care | 2 | 2017 | 588 | 0.530 |
Why?
|
| Cardiomyopathy, Dilated | 3 | 2013 | 246 | 0.530 |
Why?
|
| Heart Rate | 9 | 2019 | 765 | 0.530 |
Why?
|
| Humans | 139 | 2023 | 270605 | 0.520 |
Why?
|
| Health Literacy | 1 | 2017 | 127 | 0.520 |
Why?
|
| School Health Services | 1 | 2016 | 112 | 0.510 |
Why?
|
| Ductus Arteriosus, Patent | 3 | 2023 | 140 | 0.510 |
Why?
|
| Bile Acids and Salts | 2 | 2016 | 255 | 0.510 |
Why?
|
| Exercise Tolerance | 4 | 2023 | 111 | 0.500 |
Why?
|
| Infant, Newborn | 32 | 2021 | 8591 | 0.500 |
Why?
|
| Phosphodiesterase Inhibitors | 3 | 2006 | 68 | 0.490 |
Why?
|
| Community Health Services | 1 | 2016 | 131 | 0.480 |
Why?
|
| Global Health | 2 | 2017 | 697 | 0.480 |
Why?
|
| Cerebrovascular Circulation | 2 | 2017 | 478 | 0.470 |
Why?
|
| Postoperative Complications | 10 | 2017 | 5815 | 0.470 |
Why?
|
| Arrhythmias, Cardiac | 4 | 2009 | 517 | 0.460 |
Why?
|
| Pediatrics | 4 | 2021 | 1196 | 0.450 |
Why?
|
| Cardiovascular System | 3 | 2023 | 141 | 0.450 |
Why?
|
| Cardiac Catheterization | 7 | 2023 | 760 | 0.450 |
Why?
|
| Echocardiography | 13 | 2020 | 1262 | 0.440 |
Why?
|
| Infant | 39 | 2023 | 13886 | 0.440 |
Why?
|
| Diastole | 8 | 2018 | 189 | 0.430 |
Why?
|
| Family | 1 | 2017 | 744 | 0.430 |
Why?
|
| Urotensins | 2 | 2010 | 4 | 0.430 |
Why?
|
| Vasodilator Agents | 7 | 2016 | 232 | 0.410 |
Why?
|
| Oxygen | 9 | 2023 | 783 | 0.410 |
Why?
|
| Cardiac Output | 10 | 2017 | 197 | 0.400 |
Why?
|
| Disease Management | 1 | 2017 | 1116 | 0.390 |
Why?
|
| Tetralogy of Fallot | 6 | 2017 | 154 | 0.390 |
Why?
|
| Communication | 2 | 2020 | 909 | 0.390 |
Why?
|
| Victoria | 6 | 2013 | 18 | 0.390 |
Why?
|
| Myocardium | 4 | 2018 | 1343 | 0.380 |
Why?
|
| Kingella kingae | 1 | 2010 | 2 | 0.370 |
Why?
|
| Female | 78 | 2023 | 147401 | 0.370 |
Why?
|
| Shock, Cardiogenic | 2 | 2023 | 284 | 0.370 |
Why?
|
| Neisseriaceae Infections | 1 | 2010 | 4 | 0.370 |
Why?
|
| Cardiovascular Surgical Procedures | 3 | 2011 | 55 | 0.360 |
Why?
|
| Male | 70 | 2023 | 127509 | 0.350 |
Why?
|
| Endocarditis, Bacterial | 2 | 2010 | 133 | 0.350 |
Why?
|
| Vascular Surgical Procedures | 1 | 2016 | 653 | 0.350 |
Why?
|
| Cardiomyopathies | 4 | 2019 | 626 | 0.350 |
Why?
|
| Vascular Fistula | 1 | 2010 | 41 | 0.350 |
Why?
|
| Hypertension | 2 | 2018 | 1574 | 0.350 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2012 | 207 | 0.350 |
Why?
|
| Parents | 1 | 2017 | 1064 | 0.350 |
Why?
|
| Cardiac Complexes, Premature | 1 | 2009 | 5 | 0.340 |
Why?
|
| Cardiac Surgical Procedures | 8 | 2019 | 1226 | 0.340 |
Why?
|
| Cardiotonic Agents | 5 | 2018 | 163 | 0.340 |
Why?
|
| Myocardial Contraction | 5 | 2018 | 304 | 0.330 |
Why?
|
| Sulfonamides | 5 | 2023 | 1907 | 0.330 |
Why?
|
| Nitric Oxide Synthase | 2 | 2001 | 318 | 0.330 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2005 | 445 | 0.330 |
Why?
|
| Piperazines | 5 | 2006 | 2143 | 0.330 |
Why?
|
| Lung | 7 | 2015 | 3233 | 0.330 |
Why?
|
| Respiration, Artificial | 8 | 2006 | 594 | 0.330 |
Why?
|
| Heart Failure | 5 | 2018 | 2674 | 0.330 |
Why?
|
| Abscess | 1 | 2010 | 178 | 0.320 |
Why?
|
| Heart Septal Defects, Atrial | 4 | 2003 | 129 | 0.310 |
Why?
|
| Endothelial Cells | 1 | 2014 | 1078 | 0.310 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2012 | 435 | 0.300 |
Why?
|
| Signal Processing, Computer-Assisted | 3 | 2007 | 215 | 0.300 |
Why?
|
| Cardiology Service, Hospital | 2 | 2006 | 16 | 0.300 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2016 | 330 | 0.290 |
Why?
|
| Ultrasonography, Prenatal | 3 | 2007 | 884 | 0.290 |
Why?
|
| Myocytes, Cardiac | 1 | 2013 | 828 | 0.290 |
Why?
|
| Adolescent | 32 | 2021 | 32427 | 0.290 |
Why?
|
| Computer Simulation | 6 | 2023 | 1528 | 0.290 |
Why?
|
| Malawi | 3 | 2019 | 379 | 0.290 |
Why?
|
| Sepsis | 2 | 2023 | 668 | 0.290 |
Why?
|
| Blood Gas Analysis | 6 | 2014 | 105 | 0.280 |
Why?
|
| Cardiac Care Facilities | 1 | 2006 | 11 | 0.280 |
Why?
|
| Systole | 6 | 2017 | 210 | 0.280 |
Why?
|
| Postoperative Period | 10 | 2020 | 670 | 0.280 |
Why?
|
| Time Factors | 13 | 2019 | 13229 | 0.280 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2005 | 659 | 0.280 |
Why?
|
| Infusions, Intravenous | 9 | 2007 | 1416 | 0.280 |
Why?
|
| Hydrazones | 3 | 2014 | 45 | 0.270 |
Why?
|
| Animals | 35 | 2019 | 61195 | 0.270 |
Why?
|
| Animals, Newborn | 5 | 2013 | 1349 | 0.270 |
Why?
|
| Length of Stay | 3 | 2016 | 2039 | 0.270 |
Why?
|
| Pulmonary Valve Stenosis | 2 | 2003 | 46 | 0.270 |
Why?
|
| Aorta, Thoracic | 1 | 2010 | 537 | 0.260 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2006 | 127 | 0.260 |
Why?
|
| Atrial Fibrillation | 1 | 2013 | 808 | 0.250 |
Why?
|
| Peptides, Cyclic | 2 | 2004 | 134 | 0.250 |
Why?
|
| Pulmonary Valve | 3 | 2020 | 100 | 0.250 |
Why?
|
| ROC Curve | 3 | 2021 | 1213 | 0.250 |
Why?
|
| Vena Cava, Superior | 3 | 1997 | 79 | 0.240 |
Why?
|
| Antiviral Agents | 1 | 2012 | 1261 | 0.240 |
Why?
|
| Body Temperature | 3 | 2004 | 163 | 0.240 |
Why?
|
| Cardiac Output, Low | 2 | 2007 | 80 | 0.240 |
Why?
|
| Algorithms | 6 | 2021 | 3974 | 0.240 |
Why?
|
| Predictive Value of Tests | 8 | 2017 | 5012 | 0.240 |
Why?
|
| Retrospective Studies | 23 | 2023 | 39678 | 0.230 |
Why?
|
| Pulsatile Flow | 4 | 2012 | 133 | 0.220 |
Why?
|
| Pyridazines | 3 | 2014 | 320 | 0.220 |
Why?
|
| Infant, Very Low Birth Weight | 3 | 2021 | 173 | 0.220 |
Why?
|
| Critical Illness | 4 | 2023 | 748 | 0.220 |
Why?
|
| Pulmonary Valve Insufficiency | 1 | 2003 | 40 | 0.220 |
Why?
|
| Electrocardiography | 6 | 2017 | 1250 | 0.220 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 2 | 2019 | 25 | 0.210 |
Why?
|
| Receptors, Endothelin | 1 | 2002 | 25 | 0.210 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2004 | 188 | 0.210 |
Why?
|
| Endothelin Receptor Antagonists | 1 | 2002 | 25 | 0.210 |
Why?
|
| Mutation | 6 | 2019 | 15649 | 0.210 |
Why?
|
| Pregnancy | 9 | 2013 | 7898 | 0.210 |
Why?
|
| Blood Pressure Determination | 2 | 2021 | 110 | 0.210 |
Why?
|
| Heart Conduction System | 1 | 2003 | 177 | 0.200 |
Why?
|
| Models, Animal | 3 | 2012 | 689 | 0.200 |
Why?
|
| Organizational Culture | 1 | 2022 | 117 | 0.200 |
Why?
|
| Prevalence | 6 | 2019 | 3393 | 0.200 |
Why?
|
| Software Validation | 1 | 2021 | 32 | 0.200 |
Why?
|
| Hypovolemia | 1 | 2021 | 12 | 0.190 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2018 | 485 | 0.190 |
Why?
|
| Disease Models, Animal | 6 | 2018 | 7455 | 0.190 |
Why?
|
| Echocardiography, Doppler | 5 | 2009 | 183 | 0.190 |
Why?
|
| Follow-Up Studies | 12 | 2019 | 15238 | 0.190 |
Why?
|
| Sildenafil Citrate | 6 | 2016 | 55 | 0.190 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2005 | 324 | 0.190 |
Why?
|
| Airway Obstruction | 2 | 2002 | 267 | 0.190 |
Why?
|
| Persistent Fetal Circulation Syndrome | 1 | 2002 | 93 | 0.190 |
Why?
|
| Postoperative Care | 4 | 2018 | 748 | 0.190 |
Why?
|
| Coronary Vessels | 2 | 2018 | 693 | 0.180 |
Why?
|
| Coronary Angiography | 2 | 2016 | 670 | 0.180 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 3380 | 0.180 |
Why?
|
| Blood Vessels | 2 | 2011 | 221 | 0.180 |
Why?
|
| Pulmonary Atresia | 1 | 2000 | 48 | 0.180 |
Why?
|
| Exercise Test | 3 | 2023 | 318 | 0.180 |
Why?
|
| Ventilators, Negative-Pressure | 1 | 2000 | 5 | 0.180 |
Why?
|
| Adrenergic Antagonists | 1 | 2000 | 19 | 0.180 |
Why?
|
| Prenatal Diagnosis | 3 | 2013 | 608 | 0.180 |
Why?
|
| Prospective Studies | 15 | 2019 | 13329 | 0.180 |
Why?
|
| Swine | 7 | 2008 | 1610 | 0.170 |
Why?
|
| Treatment Outcome | 20 | 2021 | 34259 | 0.170 |
Why?
|
| Asymptomatic Diseases | 2 | 2019 | 103 | 0.170 |
Why?
|
| Erythrocyte Transfusion | 1 | 2021 | 206 | 0.170 |
Why?
|
| Arrhythmogenic Right Ventricular Dysplasia | 1 | 2019 | 29 | 0.160 |
Why?
|
| Severity of Illness Index | 3 | 2021 | 4436 | 0.160 |
Why?
|
| Administration, Inhalation | 7 | 2006 | 298 | 0.160 |
Why?
|
| Milrinone | 2 | 2011 | 35 | 0.160 |
Why?
|
| Adaptation, Physiological | 2 | 2018 | 365 | 0.160 |
Why?
|
| Reproducibility of Results | 5 | 2016 | 6172 | 0.160 |
Why?
|
| Arteries | 2 | 2012 | 283 | 0.160 |
Why?
|
| Infant, Premature, Diseases | 1 | 2021 | 257 | 0.160 |
Why?
|
| Cholic Acids | 1 | 2018 | 31 | 0.160 |
Why?
|
| Crowdsourcing | 1 | 2018 | 19 | 0.160 |
Why?
|
| Bioprosthesis | 1 | 2020 | 173 | 0.160 |
Why?
|
| Pyrimidines | 3 | 2023 | 3640 | 0.160 |
Why?
|
| Heterotaxy Syndrome | 1 | 2019 | 64 | 0.160 |
Why?
|
| Heart | 5 | 2023 | 1261 | 0.160 |
Why?
|
| Aortic Valve | 3 | 2020 | 634 | 0.150 |
Why?
|
| Lead | 1 | 2018 | 56 | 0.150 |
Why?
|
| Drug-Eluting Stents | 1 | 2019 | 141 | 0.150 |
Why?
|
| Pulse Wave Analysis | 1 | 2018 | 48 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2019 | 5413 | 0.150 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2020 | 334 | 0.150 |
Why?
|
| Zebrafish Proteins | 1 | 2019 | 161 | 0.150 |
Why?
|
| Exome | 3 | 2019 | 1262 | 0.150 |
Why?
|
| Machine Learning | 1 | 2021 | 362 | 0.150 |
Why?
|
| Heart-Assist Devices | 2 | 2022 | 1219 | 0.150 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2021 | 270 | 0.150 |
Why?
|
| Hypotension | 2 | 2015 | 215 | 0.150 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2017 | 45 | 0.150 |
Why?
|
| Sulfones | 5 | 2006 | 147 | 0.150 |
Why?
|
| Models, Organizational | 1 | 2017 | 75 | 0.140 |
Why?
|
| Hepatic Veins | 1 | 2017 | 61 | 0.140 |
Why?
|
| Aortic Valve Insufficiency | 2 | 2011 | 170 | 0.140 |
Why?
|
| Exercise | 3 | 2023 | 1217 | 0.140 |
Why?
|
| Cross-Sectional Studies | 6 | 2021 | 4535 | 0.140 |
Why?
|
| Nonlinear Dynamics | 3 | 2015 | 79 | 0.140 |
Why?
|
| Everolimus | 1 | 2019 | 425 | 0.140 |
Why?
|
| Long QT Syndrome | 1 | 2018 | 111 | 0.140 |
Why?
|
| Purines | 5 | 2006 | 274 | 0.140 |
Why?
|
| Vasodilation | 3 | 2010 | 214 | 0.140 |
Why?
|
| Nutrition Surveys | 1 | 2018 | 319 | 0.140 |
Why?
|
| Embolization, Therapeutic | 1 | 2002 | 598 | 0.140 |
Why?
|
| GTP Phosphohydrolases | 1 | 2019 | 339 | 0.140 |
Why?
|
| Intubation, Intratracheal | 1 | 2021 | 454 | 0.140 |
Why?
|
| Cerebrovascular Disorders | 1 | 2017 | 153 | 0.140 |
Why?
|
| Genome-Wide Association Study | 2 | 2016 | 2086 | 0.140 |
Why?
|
| Growth Differentiation Factors | 1 | 2016 | 12 | 0.130 |
Why?
|
| Morbidity | 1 | 2017 | 412 | 0.130 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2023 | 160 | 0.130 |
Why?
|
| Biliary Atresia | 1 | 2019 | 198 | 0.130 |
Why?
|
| Preoperative Care | 4 | 2023 | 1554 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2016 | 62 | 0.130 |
Why?
|
| Transition to Adult Care | 1 | 2018 | 112 | 0.130 |
Why?
|
| Respiratory Tract Diseases | 1 | 2016 | 115 | 0.130 |
Why?
|
| Observer Variation | 2 | 2016 | 714 | 0.130 |
Why?
|
| Interprofessional Relations | 1 | 2017 | 219 | 0.130 |
Why?
|
| Hospitals, Pediatric | 2 | 2018 | 793 | 0.130 |
Why?
|
| Respiratory System | 1 | 2016 | 127 | 0.130 |
Why?
|
| Incidence | 3 | 2019 | 5883 | 0.130 |
Why?
|
| Congresses as Topic | 1 | 2017 | 308 | 0.130 |
Why?
|
| Heart Valve Prosthesis | 1 | 2020 | 430 | 0.130 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2010 | 316 | 0.130 |
Why?
|
| Quality of Life | 1 | 2009 | 4734 | 0.130 |
Why?
|
| Genetic Variation | 3 | 2019 | 2029 | 0.130 |
Why?
|
| Exercise Therapy | 1 | 2018 | 287 | 0.120 |
Why?
|
| Capillaries | 1 | 2015 | 102 | 0.120 |
Why?
|
| Kv1.5 Potassium Channel | 1 | 2014 | 9 | 0.120 |
Why?
|
| Fetal Heart | 1 | 1995 | 109 | 0.120 |
Why?
|
| Sex Distribution | 1 | 2016 | 502 | 0.120 |
Why?
|
| Genetic Testing | 3 | 2019 | 1672 | 0.120 |
Why?
|
| Hospitalization | 2 | 2016 | 2217 | 0.120 |
Why?
|
| Amino Acids | 1 | 2018 | 760 | 0.120 |
Why?
|
| Diagnosis, Differential | 4 | 2010 | 4863 | 0.120 |
Why?
|
| Analysis of Variance | 4 | 2010 | 2285 | 0.120 |
Why?
|
| Microcirculation | 1 | 2015 | 206 | 0.120 |
Why?
|
| Health Surveys | 1 | 2016 | 414 | 0.120 |
Why?
|
| Age Distribution | 1 | 2016 | 711 | 0.120 |
Why?
|
| Cholic Acid | 1 | 2014 | 18 | 0.120 |
Why?
|
| Hospital Costs | 1 | 2016 | 247 | 0.120 |
Why?
|
| Periodicals as Topic | 1 | 2018 | 343 | 0.120 |
Why?
|
| Tachycardia, Ventricular | 1 | 2017 | 260 | 0.120 |
Why?
|
| Gonadal Dysgenesis | 1 | 2013 | 3 | 0.120 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2020 | 612 | 0.110 |
Why?
|
| Learning | 1 | 2017 | 433 | 0.110 |
Why?
|
| Weill-Marchesani Syndrome | 1 | 2013 | 1 | 0.110 |
Why?
|
| Norwood Procedures | 2 | 2013 | 98 | 0.110 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2014 | 461 | 0.110 |
Why?
|
| Receptor, Endothelin A | 2 | 2004 | 20 | 0.110 |
Why?
|
| Consensus | 1 | 2018 | 1110 | 0.110 |
Why?
|
| Mexican Americans | 1 | 2016 | 322 | 0.110 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2014 | 68 | 0.110 |
Why?
|
| Anxiety | 1 | 2021 | 1243 | 0.110 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 4342 | 0.110 |
Why?
|
| Heart Diseases | 1 | 2019 | 758 | 0.110 |
Why?
|
| Ischemic Preconditioning | 1 | 2013 | 20 | 0.110 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 2013 | 64 | 0.110 |
Why?
|
| Cyanosis | 1 | 2013 | 39 | 0.110 |
Why?
|
| Coronary Care Units | 1 | 2012 | 49 | 0.110 |
Why?
|
| Pulmonary Wedge Pressure | 2 | 2002 | 66 | 0.100 |
Why?
|
| Infant Mortality | 1 | 2013 | 188 | 0.100 |
Why?
|
| Plasmids | 1 | 2014 | 843 | 0.100 |
Why?
|
| Homeostasis | 1 | 2017 | 943 | 0.100 |
Why?
|
| Psychometrics | 1 | 2017 | 962 | 0.100 |
Why?
|
| Palivizumab | 1 | 2012 | 65 | 0.100 |
Why?
|
| Patient Admission | 1 | 2013 | 232 | 0.100 |
Why?
|
| Hypoxia, Brain | 1 | 2011 | 32 | 0.100 |
Why?
|
| Myocardial Ischemia | 1 | 2016 | 450 | 0.100 |
Why?
|
| Ventilator Weaning | 3 | 2002 | 34 | 0.100 |
Why?
|
| Biomarkers | 6 | 2018 | 5149 | 0.100 |
Why?
|
| Cholestasis | 1 | 2014 | 208 | 0.100 |
Why?
|
| Advisory Committees | 1 | 2012 | 217 | 0.100 |
Why?
|
| Certification | 1 | 2012 | 127 | 0.100 |
Why?
|
| Marfan Syndrome | 1 | 2013 | 149 | 0.100 |
Why?
|
| Liver Cirrhosis | 1 | 2019 | 1003 | 0.100 |
Why?
|
| Airway Extubation | 1 | 2012 | 73 | 0.100 |
Why?
|
| Anastomosis, Surgical | 4 | 2007 | 375 | 0.100 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 637 | 0.100 |
Why?
|
| Eisenmenger Complex | 1 | 2011 | 7 | 0.100 |
Why?
|
| Cardiac Volume | 1 | 2011 | 19 | 0.100 |
Why?
|
| Thoracic Surgery | 2 | 2013 | 290 | 0.100 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2011 | 14 | 0.100 |
Why?
|
| Oral Hygiene | 1 | 2011 | 20 | 0.100 |
Why?
|
| Databases, Factual | 2 | 2016 | 2309 | 0.100 |
Why?
|
| Action Potentials | 3 | 2004 | 602 | 0.090 |
Why?
|
| Aptamers, Peptide | 1 | 2010 | 3 | 0.090 |
Why?
|
| Enkephalin, Methionine | 1 | 2010 | 12 | 0.090 |
Why?
|
| Heart Function Tests | 2 | 2008 | 73 | 0.090 |
Why?
|
| Patient Discharge | 1 | 2016 | 719 | 0.090 |
Why?
|
| Depression | 1 | 2021 | 1741 | 0.090 |
Why?
|
| Nitroarginine | 2 | 2001 | 11 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2007 | 5023 | 0.090 |
Why?
|
| Benchmarking | 1 | 2012 | 290 | 0.090 |
Why?
|
| Heart Bypass, Right | 1 | 2010 | 18 | 0.090 |
Why?
|
| Rupture, Spontaneous | 1 | 2010 | 71 | 0.090 |
Why?
|
| American Heart Association | 1 | 2012 | 363 | 0.090 |
Why?
|
| Carbon Dioxide | 2 | 2009 | 321 | 0.090 |
Why?
|
| Mitral Valve | 1 | 1992 | 307 | 0.090 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2010 | 35 | 0.090 |
Why?
|
| Microfilament Proteins | 1 | 2013 | 496 | 0.090 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2011 | 121 | 0.090 |
Why?
|
| Aptamers, Nucleotide | 1 | 2010 | 62 | 0.090 |
Why?
|
| Texas | 3 | 2016 | 6479 | 0.090 |
Why?
|
| Hypogonadism | 1 | 2013 | 257 | 0.090 |
Why?
|
| Ventricular Pressure | 2 | 2001 | 47 | 0.090 |
Why?
|
| Lower Extremity | 1 | 2013 | 299 | 0.090 |
Why?
|
| Ultrasonography | 2 | 2007 | 1927 | 0.090 |
Why?
|
| History, 20th Century | 1 | 2012 | 584 | 0.090 |
Why?
|
| Adenosine | 1 | 2012 | 294 | 0.090 |
Why?
|
| Survival Rate | 6 | 2017 | 12469 | 0.090 |
Why?
|
| Cells, Cultured | 2 | 2018 | 5679 | 0.090 |
Why?
|
| Liver Transplantation | 1 | 2019 | 1169 | 0.090 |
Why?
|
| Chromosome Disorders | 1 | 2012 | 417 | 0.090 |
Why?
|
| Sinus of Valsalva | 1 | 2010 | 57 | 0.090 |
Why?
|
| Debridement | 1 | 2010 | 123 | 0.090 |
Why?
|
| DNA | 1 | 2018 | 2732 | 0.090 |
Why?
|
| Fatal Outcome | 3 | 2013 | 833 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 2717 | 0.080 |
Why?
|
| Exons | 1 | 2013 | 1346 | 0.080 |
Why?
|
| Catheterization | 2 | 2003 | 435 | 0.080 |
Why?
|
| Endocarditis | 1 | 2011 | 138 | 0.080 |
Why?
|
| Transfection | 1 | 2014 | 2985 | 0.080 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2011 | 210 | 0.080 |
Why?
|
| Oscillometry | 1 | 2008 | 25 | 0.080 |
Why?
|
| Respiration | 1 | 1991 | 452 | 0.080 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2010 | 233 | 0.080 |
Why?
|
| United States | 3 | 2018 | 16313 | 0.080 |
Why?
|
| Respiratory Mechanics | 2 | 2000 | 174 | 0.080 |
Why?
|
| Biological Clocks | 1 | 2008 | 45 | 0.080 |
Why?
|
| Heart Auscultation | 1 | 2008 | 10 | 0.080 |
Why?
|
| Intensive Care Units | 1 | 2013 | 746 | 0.080 |
Why?
|
| Heart Murmurs | 1 | 2008 | 16 | 0.080 |
Why?
|
| Angiography | 2 | 2019 | 361 | 0.080 |
Why?
|
| Urea | 1 | 2010 | 291 | 0.080 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2009 | 598 | 0.080 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 1090 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2010 | 334 | 0.080 |
Why?
|
| Drug Design | 1 | 2010 | 383 | 0.080 |
Why?
|
| Brain Injuries | 1 | 2014 | 753 | 0.080 |
Why?
|
| Infant, Premature | 2 | 2021 | 831 | 0.080 |
Why?
|
| Manometry | 1 | 2007 | 77 | 0.070 |
Why?
|
| Mutation, Missense | 1 | 2013 | 1185 | 0.070 |
Why?
|
| Drug Discovery | 1 | 2010 | 334 | 0.070 |
Why?
|
| Terminal Care | 1 | 2012 | 467 | 0.070 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2007 | 62 | 0.070 |
Why?
|
| Body Size | 1 | 2007 | 68 | 0.070 |
Why?
|
| Heart Block | 1 | 2007 | 50 | 0.070 |
Why?
|
| Growth | 1 | 2007 | 119 | 0.070 |
Why?
|
| Hypoxia | 1 | 2010 | 458 | 0.070 |
Why?
|
| Age Factors | 5 | 2007 | 5487 | 0.070 |
Why?
|
| Rhamnose | 1 | 1986 | 3 | 0.070 |
Why?
|
| Adult | 15 | 2020 | 80769 | 0.070 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2013 | 552 | 0.070 |
Why?
|
| Balloon Occlusion | 1 | 2007 | 60 | 0.070 |
Why?
|
| Disaccharides | 1 | 1986 | 32 | 0.070 |
Why?
|
| Lactulose | 1 | 1986 | 38 | 0.070 |
Why?
|
| Abnormalities, Multiple | 2 | 2005 | 1010 | 0.070 |
Why?
|
| Electroencephalography | 1 | 2011 | 939 | 0.070 |
Why?
|
| Fetal Diseases | 3 | 2001 | 415 | 0.070 |
Why?
|
| Pyridines | 1 | 2014 | 1299 | 0.070 |
Why?
|
| Quinolines | 1 | 2010 | 401 | 0.070 |
Why?
|
| Gases | 1 | 2006 | 38 | 0.070 |
Why?
|
| Fetal Blood | 1 | 2009 | 487 | 0.070 |
Why?
|
| HIV Infections | 1 | 2019 | 2211 | 0.070 |
Why?
|
| Pattern Recognition, Automated | 1 | 2007 | 127 | 0.070 |
Why?
|
| Cohort Studies | 5 | 2019 | 9447 | 0.070 |
Why?
|
| RNA Interference | 1 | 2010 | 1410 | 0.070 |
Why?
|
| Infant Welfare | 2 | 2002 | 23 | 0.070 |
Why?
|
| Intestinal Absorption | 1 | 1986 | 220 | 0.070 |
Why?
|
| Telemedicine | 1 | 2012 | 549 | 0.070 |
Why?
|
| Pregnancy Complications | 1 | 2011 | 544 | 0.070 |
Why?
|
| Incontinentia Pigmenti | 1 | 2005 | 15 | 0.060 |
Why?
|
| Obesity | 1 | 2018 | 2981 | 0.060 |
Why?
|
| Gestational Age | 1 | 2009 | 1110 | 0.060 |
Why?
|
| DNA Copy Number Variations | 1 | 2012 | 1546 | 0.060 |
Why?
|
| Ventilation-Perfusion Ratio | 1 | 2005 | 8 | 0.060 |
Why?
|
| Equipment Safety | 1 | 2005 | 67 | 0.060 |
Why?
|
| Nitrous Oxide | 1 | 2005 | 17 | 0.060 |
Why?
|
| Replantation | 1 | 2005 | 59 | 0.060 |
Why?
|
| Quality Improvement | 1 | 2012 | 933 | 0.060 |
Why?
|
| Dopamine | 2 | 2014 | 317 | 0.060 |
Why?
|
| Gene Frequency | 2 | 2019 | 1119 | 0.060 |
Why?
|
| Reoperation | 3 | 2005 | 1442 | 0.060 |
Why?
|
| Endothelin A Receptor Antagonists | 1 | 2004 | 11 | 0.060 |
Why?
|
| Feedback, Physiological | 2 | 2004 | 196 | 0.060 |
Why?
|
| Hand Deformities, Congenital | 1 | 2005 | 89 | 0.060 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2007 | 508 | 0.060 |
Why?
|
| Liver | 1 | 2014 | 2992 | 0.060 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2005 | 165 | 0.060 |
Why?
|
| Cystic Fibrosis | 1 | 1986 | 274 | 0.060 |
Why?
|
| Models, Biological | 2 | 2010 | 3243 | 0.060 |
Why?
|
| Up-Regulation | 1 | 2010 | 2473 | 0.060 |
Why?
|
| Stem Cell Transplantation | 1 | 2010 | 1384 | 0.060 |
Why?
|
| Genetic Association Studies | 2 | 2019 | 1060 | 0.060 |
Why?
|
| Software | 2 | 2007 | 1342 | 0.060 |
Why?
|
| Neural Conduction | 1 | 2003 | 112 | 0.050 |
Why?
|
| San Francisco | 1 | 2003 | 21 | 0.050 |
Why?
|
| Sexual Behavior | 1 | 2005 | 316 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 4060 | 0.050 |
Why?
|
| Toll-Like Receptors | 1 | 2004 | 174 | 0.050 |
Why?
|
| Stroke Volume | 2 | 2008 | 604 | 0.050 |
Why?
|
| London | 1 | 2002 | 14 | 0.050 |
Why?
|
| Accidents, Traffic | 1 | 2003 | 122 | 0.050 |
Why?
|
| Genetic Therapy | 1 | 2010 | 1631 | 0.050 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2005 | 177 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2018 | 12168 | 0.050 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 1178 | 0.050 |
Why?
|
| Electrophysiology | 1 | 2003 | 351 | 0.050 |
Why?
|
| Brain | 2 | 2014 | 4147 | 0.050 |
Why?
|
| Mice, Knockout | 3 | 2018 | 5809 | 0.050 |
Why?
|
| Child Welfare | 1 | 2002 | 70 | 0.050 |
Why?
|
| Bronchoconstriction | 1 | 2002 | 22 | 0.050 |
Why?
|
| Proteins | 1 | 2010 | 1974 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2004 | 568 | 0.050 |
Why?
|
| Receptors, Adrenergic, beta-1 | 1 | 2001 | 15 | 0.050 |
Why?
|
| Chickenpox | 1 | 2001 | 31 | 0.050 |
Why?
|
| Adrenergic beta-2 Receptor Antagonists | 1 | 2001 | 18 | 0.050 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 1 | 2001 | 18 | 0.050 |
Why?
|
| Herpesvirus 3, Human | 1 | 2001 | 45 | 0.050 |
Why?
|
| Mediastinum | 1 | 2023 | 276 | 0.050 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2001 | 29 | 0.050 |
Why?
|
| Energy Metabolism | 1 | 2007 | 1011 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2014 | 7336 | 0.050 |
Why?
|
| DNA Mutational Analysis | 2 | 2018 | 2296 | 0.050 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 2001 | 39 | 0.050 |
Why?
|
| Parenting | 1 | 2005 | 352 | 0.050 |
Why?
|
| Bronchodilator Agents | 1 | 2003 | 223 | 0.050 |
Why?
|
| Prostaglandins | 1 | 2001 | 80 | 0.050 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2004 | 632 | 0.050 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2001 | 124 | 0.050 |
Why?
|
| Collateral Circulation | 1 | 2000 | 63 | 0.050 |
Why?
|
| In Vitro Techniques | 1 | 2003 | 1630 | 0.050 |
Why?
|
| Pulmonary Veins | 1 | 2002 | 183 | 0.050 |
Why?
|
| Phenotype | 3 | 2018 | 6354 | 0.050 |
Why?
|
| Physical Exertion | 1 | 2000 | 117 | 0.040 |
Why?
|
| Pre-Excitation Syndromes | 1 | 2000 | 3 | 0.040 |
Why?
|
| Risk Factors | 5 | 2017 | 17996 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2004 | 884 | 0.040 |
Why?
|
| Young Adult | 3 | 2018 | 22221 | 0.040 |
Why?
|
| Lactates | 1 | 2000 | 116 | 0.040 |
Why?
|
| Rhabdomyoma | 1 | 2000 | 22 | 0.040 |
Why?
|
| Apoptosis | 1 | 2014 | 7758 | 0.040 |
Why?
|
| Placebo Effect | 1 | 2019 | 38 | 0.040 |
Why?
|
| Palliative Care | 4 | 2007 | 2149 | 0.040 |
Why?
|
| Patient Transfer | 1 | 2001 | 139 | 0.040 |
Why?
|
| Pedigree | 2 | 2014 | 1876 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2004 | 695 | 0.040 |
Why?
|
| Desmoglein 2 | 1 | 2019 | 3 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2004 | 1054 | 0.040 |
Why?
|
| Substance P | 1 | 1999 | 71 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2003 | 1540 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2021 | 718 | 0.040 |
Why?
|
| Myocarditis | 1 | 2001 | 201 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2001 | 335 | 0.040 |
Why?
|
| Plakophilins | 1 | 2019 | 16 | 0.040 |
Why?
|
| Heart Septum | 2 | 2003 | 56 | 0.040 |
Why?
|
| Uganda | 1 | 2019 | 74 | 0.040 |
Why?
|
| Peroxidases | 1 | 2019 | 28 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 1110 | 0.040 |
Why?
|
| Iatrogenic Disease | 1 | 2020 | 184 | 0.040 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2019 | 72 | 0.040 |
Why?
|
| Sensitivity and Specificity | 3 | 2008 | 5117 | 0.040 |
Why?
|
| Stimulation, Chemical | 1 | 1998 | 95 | 0.040 |
Why?
|
| Bronchi | 1 | 2000 | 322 | 0.040 |
Why?
|
| Trachea | 1 | 2000 | 271 | 0.040 |
Why?
|
| Cytoprotection | 1 | 2018 | 66 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2019 | 2649 | 0.040 |
Why?
|
| Prosthesis Failure | 1 | 2020 | 230 | 0.040 |
Why?
|
| Pressure | 2 | 2011 | 218 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 1580 | 0.040 |
Why?
|
| Ligation | 1 | 1998 | 192 | 0.040 |
Why?
|
| Positive-Pressure Respiration | 1 | 1999 | 122 | 0.040 |
Why?
|
| Tuberous Sclerosis | 1 | 2000 | 143 | 0.040 |
Why?
|
| Body Patterning | 1 | 2019 | 212 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2009 | 10095 | 0.040 |
Why?
|
| Patients | 1 | 2020 | 257 | 0.040 |
Why?
|
| Heart Neoplasms | 1 | 2000 | 215 | 0.040 |
Why?
|
| Calsequestrin | 1 | 2017 | 13 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2005 | 1280 | 0.040 |
Why?
|
| Inheritance Patterns | 1 | 2017 | 134 | 0.040 |
Why?
|
| Bronchoscopy | 1 | 2000 | 478 | 0.040 |
Why?
|
| Incidental Findings | 1 | 2019 | 283 | 0.040 |
Why?
|
| Prosthesis Design | 1 | 2020 | 788 | 0.040 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2019 | 348 | 0.040 |
Why?
|
| Reference Values | 1 | 1999 | 1123 | 0.030 |
Why?
|
| Genotype | 2 | 2016 | 4002 | 0.030 |
Why?
|
| Growth Differentiation Factor 2 | 1 | 2016 | 4 | 0.030 |
Why?
|
| Embryonic Development | 1 | 2019 | 318 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2017 | 308 | 0.030 |
Why?
|
| Arginine | 1 | 1999 | 516 | 0.030 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2017 | 76 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2017 | 317 | 0.030 |
Why?
|
| Zebrafish | 1 | 2019 | 463 | 0.030 |
Why?
|
| Chest Pain | 1 | 2017 | 171 | 0.030 |
Why?
|
| Compliance | 1 | 2015 | 16 | 0.030 |
Why?
|
| Epoprostenol | 1 | 2016 | 79 | 0.030 |
Why?
|
| Stochastic Processes | 1 | 2015 | 47 | 0.030 |
Why?
|
| Equipment Design | 2 | 2011 | 1229 | 0.030 |
Why?
|
| Codon, Nonsense | 1 | 2016 | 161 | 0.030 |
Why?
|
| Cineangiography | 1 | 1995 | 23 | 0.030 |
Why?
|
| Prognosis | 3 | 2018 | 22349 | 0.030 |
Why?
|
| Stents | 1 | 2002 | 1141 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2018 | 7213 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 1999 | 904 | 0.030 |
Why?
|
| Infection Control | 1 | 2017 | 279 | 0.030 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 2017 | 246 | 0.030 |
Why?
|
| Warfarin | 1 | 2016 | 157 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2017 | 921 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2001 | 1949 | 0.030 |
Why?
|
| Fibrillins | 1 | 2013 | 35 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2016 | 460 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 3512 | 0.030 |
Why?
|
| Lamin Type A | 1 | 2013 | 19 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2017 | 751 | 0.030 |
Why?
|
| Fibrillin-1 | 1 | 2013 | 59 | 0.030 |
Why?
|
| Homozygote | 1 | 2016 | 734 | 0.030 |
Why?
|
| Tourniquets | 1 | 2013 | 15 | 0.030 |
Why?
|
| Patient Selection | 1 | 2001 | 2104 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2021 | 902 | 0.030 |
Why?
|
| Thrombosis | 1 | 2019 | 807 | 0.030 |
Why?
|
| Alleles | 1 | 2019 | 2388 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2016 | 4320 | 0.030 |
Why?
|
| Perioperative Care | 1 | 2017 | 447 | 0.030 |
Why?
|
| Carotid Arteries | 1 | 2014 | 256 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2023 | 7888 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2021 | 986 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2019 | 1433 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2019 | 7084 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 2040 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2016 | 1433 | 0.030 |
Why?
|
| Disease Progression | 2 | 2019 | 6865 | 0.030 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2014 | 247 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2014 | 597 | 0.030 |
Why?
|
| Neuroglia | 1 | 2014 | 236 | 0.030 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2014 | 314 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2012 | 173 | 0.030 |
Why?
|
| Troponin I | 1 | 2013 | 134 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2011 | 2341 | 0.020 |
Why?
|
| Eye Abnormalities | 1 | 2012 | 113 | 0.020 |
Why?
|
| Protein Interaction Maps | 1 | 2012 | 149 | 0.020 |
Why?
|
| Thorax | 1 | 1992 | 219 | 0.020 |
Why?
|
| Rheology | 1 | 2011 | 55 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2012 | 249 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2017 | 936 | 0.020 |
Why?
|
| Viscosity | 1 | 2011 | 50 | 0.020 |
Why?
|
| Aneuploidy | 1 | 2012 | 373 | 0.020 |
Why?
|
| Time-to-Treatment | 1 | 2013 | 317 | 0.020 |
Why?
|
| Perioperative Period | 1 | 2011 | 152 | 0.020 |
Why?
|
| Ebstein Anomaly | 1 | 2010 | 26 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2018 | 2279 | 0.020 |
Why?
|
| Genome, Human | 1 | 2019 | 1852 | 0.020 |
Why?
|
| Anesthesia | 2 | 2004 | 293 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2011 | 326 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2014 | 716 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2016 | 847 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2012 | 876 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 1255 | 0.020 |
Why?
|
| Esophagus | 1 | 1992 | 560 | 0.020 |
Why?
|
| Oximetry | 1 | 2010 | 181 | 0.020 |
Why?
|
| Energy Transfer | 1 | 2008 | 36 | 0.020 |
Why?
|
| Tonga | 1 | 2008 | 1 | 0.020 |
Why?
|
| Stethoscopes | 1 | 2008 | 8 | 0.020 |
Why?
|
| Patient Care Planning | 1 | 2010 | 307 | 0.020 |
Why?
|
| Medical Audit | 1 | 2009 | 190 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 985 | 0.020 |
Why?
|
| Genomics | 1 | 2019 | 2846 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2014 | 1163 | 0.020 |
Why?
|
| Time | 1 | 2007 | 182 | 0.020 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2007 | 41 | 0.020 |
Why?
|
| Computers | 1 | 2007 | 141 | 0.020 |
Why?
|
| Automation | 1 | 2007 | 155 | 0.020 |
Why?
|
| Malabsorption Syndromes | 1 | 1986 | 55 | 0.020 |
Why?
|
| Sex Education | 1 | 2005 | 25 | 0.020 |
Why?
|
| Catheters, Indwelling | 1 | 2008 | 382 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2007 | 759 | 0.020 |
Why?
|
| Noble Gases | 1 | 2005 | 1 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 5943 | 0.020 |
Why?
|
| Registries | 1 | 2013 | 2300 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2011 | 1164 | 0.020 |
Why?
|
| Pacemaker, Artificial | 1 | 2007 | 225 | 0.010 |
Why?
|
| Constriction | 1 | 2004 | 56 | 0.010 |
Why?
|
| Respiratory Function Tests | 1 | 2005 | 337 | 0.010 |
Why?
|
| Karyotyping | 1 | 2005 | 1030 | 0.010 |
Why?
|
| Reproduction | 1 | 2005 | 259 | 0.010 |
Why?
|
| Intensive Care, Neonatal | 1 | 2003 | 55 | 0.010 |
Why?
|
| Stress, Mechanical | 1 | 2004 | 317 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 7710 | 0.010 |
Why?
|
| Hypothermia, Induced | 1 | 2004 | 178 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2007 | 794 | 0.010 |
Why?
|
| Lactic Acid | 1 | 2004 | 310 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2007 | 1977 | 0.010 |
Why?
|
| Health Status | 1 | 2005 | 610 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2007 | 1390 | 0.010 |
Why?
|
| Injections, Intra-Arterial | 1 | 2000 | 63 | 0.010 |
Why?
|
| Syndrome | 1 | 2004 | 1372 | 0.010 |
Why?
|
| Survival Analysis | 2 | 2006 | 9301 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2003 | 723 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 2004 | 336 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2003 | 1340 | 0.010 |
Why?
|
| Hydrops Fetalis | 1 | 2000 | 69 | 0.010 |
Why?
|
| Tachycardia | 1 | 2000 | 80 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2007 | 1686 | 0.010 |
Why?
|
| Mesenteric Artery, Superior | 1 | 1999 | 72 | 0.010 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2001 | 219 | 0.010 |
Why?
|
| Ultrasonography, Doppler | 1 | 1999 | 262 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2000 | 481 | 0.010 |
Why?
|
| Cesarean Section | 1 | 2000 | 384 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2005 | 5989 | 0.010 |
Why?
|
| Linear Models | 1 | 1999 | 1086 | 0.010 |
Why?
|
| Mice | 1 | 2016 | 35470 | 0.010 |
Why?
|
| Methods | 1 | 1993 | 190 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1993 | 165 | 0.010 |
Why?
|
| Inflammation | 1 | 2001 | 2555 | 0.010 |
Why?
|
| Staphylococcal Infections | 1 | 1995 | 679 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2002 | 7753 | 0.000 |
Why?
|
| Aged | 1 | 2005 | 72892 | 0.000 |
Why?
|
| Middle Aged | 1 | 2005 | 89520 | 0.000 |
Why?
|